New Study Finds GLP-1 Medications May Reduce Risk of Violent Behavior

Rutgers University researchers report that GLP-1 receptor agonists, medicines commonly used for type 2 diabetes and obesity, may influence behavior beyond metabolic effects. The study, published in Criminology, analyzes data from a 2025 nationwide survey of more than 7,500 U.S. adults and focuses on 821 respondents with a history of GLP-1 use, comparing current to former users. Behavioral measures rely on validated self-report scales that encompass acts ranging from physical fights to more serious offenses. The researchers explore whether ongoing GLP-1 activity moderates links among impulsivity, alcohol use, and violent conduct. A key finding indicates that the link between impulsivity and violent behavior is about 62% weaker among current GLP-1 users than among those who have discontinued use. Among current users, the association between alcohol consumption and violent behavior is reduced by roughly 52% compared with former users. The authors caution that results varied across analytic approaches, signaling the need for further study to confirm mechanisms and generalizability. These results add a new dimension to GLP-1 medications, suggesting potential neurobehavioral effects beyond metabolic control, and indicate a need for continued research to validate findings and determine clinical relevance.